Pyxis Oncology, Inc. (PYXS): Price and Financial Metrics
PYXS Price/Volume Stats
| Current price | $4.57 | 52-week high | $6.85 |
| Prev. close | $4.38 | 52-week low | $1.35 |
| Day low | $4.57 | Volume | 704 |
| Day high | $4.57 | Avg. volume | 753,887 |
| 50-day MA | $5.06 | Dividend yield | N/A |
| 200-day MA | $3.00 | Market Cap | 269.06M |
PYXS Stock Price Chart Interactive Chart >
Pyxis Oncology, Inc. (PYXS) Company Bio
Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest PYXS News From Around the Web
Below are the latest news stories about PYXIS ONCOLOGY INC that investors may wish to consider to help them evaluate PYXS as an investment opportunity.
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical OfficerDr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalitiesBOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer (CMO), effective November 27, 2023. Dr. Kobayashi brings extensive |
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate UpdatePYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 (a fully human immunotherapy antibody candidate): Phase 1 trial now focusing on NSCLC and other tumor types; data expected 2H 2024. Cash runway extended to early 2026 due to cost reductions and portfolio prioritization, allows for preliminary data readouts from PYX-201 and PYX-106 |
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for four different assets have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego. “We look forward to presenting a trial-in-progress poster for PYX-201, our first-in-class a |
Insider Sell: President and CEO Lara Sullivan Sells 27,917 Shares of Pyxis Oncology IncOn September 13, 2023, Lara Sullivan, President and CEO of Pyxis Oncology Inc (NASDAQ:PYXS), sold 27,917 shares of the company. |
Pyxis Oncology to Participate in Two Upcoming Investment ConferencesBOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced its participation in two upcoming investment conferences. On September 6, 2023, members of the Pyxis Oncology executive team will host in-person 1x1 meetings with investors during the 2023 Wells Fargo Healthcare Conference in Boston. To schedule a meeting, please reach out to your Wells Far |
PYXS Price Returns
| 1-mo | -16.30% |
| 3-mo | 18.70% |
| 6-mo | 180.37% |
| 1-year | 58.13% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 153.89% |
| 2023 | 34.33% |
| 2022 | -87.78% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...